Reply to: CT and PET/CT Surveillance in Stage IIIA-D Melanoma Results in More False-Positive Than True-Positive Findings and Should Not be Routinely Recommended, by Nicholas Taylor et al

Affiliations

• ¹ NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, Australia. mbathio.dieng@sydney.edu.au.
• ² School of Public Health, The University of Sydney, Camperdown, Australia. mbathio.dieng@sydney.edu.au.
• ³ NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, Australia.
• ⁴ Melanoma Institute Australia, Wollstonecraft, Australia.
• ⁵ Sydney Medical School, The University of Sydney, Camperdown, Australia.
• ⁶ Department of Medicine, Seymour, Paul, and Gloria Milstein Division of Cardiology, Columbia University Irving Medical Center, New York, USA.
• ⁷ Department of Radiology, Seymour, Paul, and Gloria Milstein Division of Cardiology, Columbia University Irving Medical Center, New York, USA.
• ⁸ Biostatistics, University of Otago, Dunedin, New Zealand.